Optimizing Treatment of Antimicrobial-resistantNeisseria gonorrhoeae
Open Access
- 1 August 2005
- journal article
- research article
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 11 (8), 1265-1273
- https://doi.org/10.3201/eid1108.050157
Abstract
Optimal point to switch to more expensive drug depends on prevalence of drug resistance andKeywords
This publication has 24 references indexed in Scilit:
- Laboratory Tests Used in U.S. Public Health Laboratories for Sexually Transmitted Diseases, 2000Sexually Transmitted Diseases, 2004
- Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men--United States, 2003, and revised recommendations for gonorrhea treatment, 2004.2004
- Increasing incidence of ciprofloxacin-resistant Neisseria gonorrhoeae infection in Canada.2003
- Increases in fluoroquinolone-resistant Neisseria gonorrhoeae--Hawaii and California, 2001.2002
- Sexually Transmitted Diseases and the Increased Risk for HIV Transmission: Implications for Cost-Effectiveness Analyses of Sexually Transmitted Disease Prevention InterventionsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Sexually Transmitted Diseases and the Increased Risk for HIV Transmission: Implications for Cost-Effectiveness Analyses of Sexually Transmitted Disease Prevention InterventionsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Delayed Presentation to Clinics for Sexually Transmitted Diseases by Symptomatic PatientsSexually Transmitted Diseases, 1997
- The Lifetime Cost of Treating a Person With HIVJAMA, 1993
- Cost of and Payment Source for Pelvic Inflammatory DiseaseJAMA, 1991
- The Incremental Cost of Screening, Diagnosis, and Treatment of Gonorrhea and Chlamydia in a Family Planning ClinicSexually Transmitted Diseases, 1989